Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Crofelemer

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,624Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Jaguar Health Doses 1st Patient in Short Bowel Syndrome Trial
    Jaguar Health Doses 1st Patient in Short Bowel Syndrome Trial

    03 Feb 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-announces-first-patient-dosed-in-short-bowel-syndrome-wi-978391

    ACCESSWIRE
    03 Feb 2025
    Share Share
    Jaguar Health Backs Crofelemer For GLP-1 GI Side Effects
    Jaguar Health Backs Crofelemer For GLP-1 GI Side Effects

    29 Jan 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-supports-evaluation-of-fda-approved-crofelemer-to-addres-975322

    ACCESSWIRE
    29 Jan 2025
    Share Share
    Jaguar Health Doses 1st Patient In Evaluating Crofelemer For MVID
    Jaguar Health Doses 1st Patient In Evaluating Crofelemer For MVID

    22 Jan 2025

    // YAHOOFINANCE

    https://finance.yahoo.com/news/jaguar-health-announces-first-patient-140000917.html

    YAHOOFINANCE
    22 Jan 2025
    Share Share
    FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer
    FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer

    17 Dec 2024

    // ACCESSWIRE

    https://www.accesswire.com/956096/fda-approves-orphan-drug-designation-for-jaguar-healths-crofelemer-for-treatment-of-diarrhea-in-cholera

    ACCESSWIRE
    17 Dec 2024
    Share Share
    Jaguar’s Crofelemer Show Positive Results For CTD In Breast Cancer
    Jaguar’s Crofelemer Show Positive Results For CTD In Breast Cancer

    12 Dec 2024

    // ACCESSWIRE

    https://www.accesswire.com/952069/significant-positive-results-with-jaguar-healths-crofelemer-for-cancer-therapy-related-diarrhea-ctd-in-breast-cancer-patients-presented-at-san-antonio-breast-cancer-symposium-sabcs

    ACCESSWIRE
    12 Dec 2024
    Share Share
    Crofelemer for Cancer Therapy-Related Diarrhea Presented at SABCS
    Crofelemer for Cancer Therapy-Related Diarrhea Presented at SABCS

    09 Dec 2024

    // ACCESSWIRE

    https://www.accesswire.com/951431/poster-presentation-describing-the-significant-results-of-crofelemer-for-cancer-therapy-related-diarrhea-ctd-in-breast-cancer-patients-to-take-place-december-11-2024-at-san-antonio-breast-cancer-symposium-sabcs

    ACCESSWIRE
    09 Dec 2024
    Share Share